

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Pirfenidone**

**INITIATION – idiopathic pulmonary fibrosis**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist

and

- ☐ Forced vital capacity is between 50% and 90% predicted

and

- ☐ Pirfenidone is to be discontinued at disease progression (See Notes)

and

- ☐ Pirfenidone is not to be used in combination with subsidised nintedanib

and

- ☐ The patient has not previously received treatment with nintedanib  
or  
☐ Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance  
or  
☐ Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib)

**CONTINUATION – idiopathic pulmonary fibrosis**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment

and

- ☐ Pirfenidone is not to be used in combination with subsidised nintedanib

and

- ☐ Pirfenidone is to be discontinued at disease progression (See Note)

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

I confirm that the above details are correct:

Signed: ..... Date: .....